

Supporting Information for

Binding studies of the prodrug HAO472 to SARS-Cov-2 Nsp9 and variants

Miaomiao Liu,[†] Dene R. Littler,[‡] Jamie Rossjohn,^{#‡} Ronald J Quinn^{†*}

[†]Griffith Institute for Drug Discovery, Griffith University, Brisbane, Queensland, Australia

[‡]Infection and Immunity Program & Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia

[#]Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom

* r.quinn@griffith.edu.au

Table of Contents

Figure S1: Comparison of native MS spectra of oridonin (**1**) binding to three Nsp9 homologues at 10 μ M and 30 μ M.

Figure S2: Comparison of native MS spectra of HAO472 (**2**) binding to three Nsp9 homologues at 1 μ M and 10 μ M.




Figure S1. Comparison of native MS spectra of oridonin (1) binding to three Nsp9 homologues at 10 μM and 30 μM. Only charge state 6+ was shown in the spectra.




Figure S2. Comparison of native MS spectra of HAO472 (2) binding to three Nsp9 homologues at 1 μM and 10 μM. Only charge state 6+ was shown in the spectra.